Inscobee Inc. - 12 May 2025 Form 4/A - Amendment Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Reporting relationship: 10%+ Owner
Issuer ticker: APUS
Reported as of: 12 May 2025
Net transaction value: +$598,681
SEC form: 4/A - Amendment
Accepted by SEC: 11 Jun 2025, 16:36:32 UTC
Original report date: 14 May 2025
Prior SEC filing: 14 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact

Key filing fact

Inscobee Inc. filed Form 4/A - Amendment for Apimeds Pharmaceuticals US, Inc. (APUS) on 11 Jun 2025.

Key facts

This page summarizes Inscobee Inc.'s Form 4/A - Amendment filing for Apimeds Pharmaceuticals US, Inc. (APUS).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Jun 2025, 16:36.

Change

Previous filing in this sequence was filed on 14 May 2025.
Current net transaction value: +$598,681.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002057997 Primary reporting owner

Inscobee Inc.

Relationship: 10%+ Owner
Address: ROOM 613, DIGITAL-RO 130, 6F, GEUMCHEON-GU, SEOUL, KOREA, REPUBLIC OF
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Signature date: 11 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APUS transaction

Common Stock, par value $0.01 per share

Conversion of derivative security

Transaction value: $184,834
Shares: +71,090
Change %: +3.6%
Price: $2.60
Shares after: 2,055,706
Date: 12 May 2025
Ownership: Direct
Footnotes: F1, F2

APUS transaction

Common Stock, par value $0.01 per share

Conversion of derivative security

Transaction value: $114,507
Shares: +44,041
Change %: +2.1%
Price: $2.60
Shares after: 2,099,747
Date: 12 May 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APUS transaction Derivative

Convertible Promissory Note

Conversion of derivative security

Transaction value: $184,833
Shares
Change %
Price
Shares after: 0
Date: 12 May 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 71,090
Exercise price: $2.60
Footnotes: F1, F2

APUS transaction Derivative

Convertible Promissory Note

Conversion of derivative security

Transaction value: $114,507
Shares
Change %
Price
Shares after: 0
Date: 12 May 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 44,041
Exercise price: $2.60
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On March 21, 2022, Apimeds Pharmaceuticals US, Inc. (the "Issuer") issued to Inscobee Inc. ("Inscobee") a convertible promissory note in the principal amount of $160,000 (as amended, the "March 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the March 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of an offering of the Issuer's common stock resulting in the listing of the Issuer's common stock on the NYSE American, or other national securities exchange (a "Qualified Offering"). The March 2022 Note bears interest at an annual rate of 5%. The March 2022 Note is convertible into shares of common stock at a conversion price of $2.60 per share (the "Conversion Price"). The amount reported in Column 3 of Table II represents the original principal amount of $160,000, plus $24,833 of accrued and unpaid interest.

Footnote F2

On May 12, 2025, the Issuer completed a Qualified Financing and all outstanding principal and accrued and unpaid interest owed under the note converted into common stock at the Conversion Price.

Footnote F3

On June 3, 2022, the Issuer issued to Inscobee a convertible promissory note in the principal amount of $100,000 (as amended, the "June 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the June 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The June 2022 Note bears interest at an annual rate of 5%. The June 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $100,000, plus $14,507 of accrued and unpaid interest.

SEC remarks

On May 14, 2025, the reporting person filed a Form 4, which incorrectly reported that the reporting person had indirect beneficial ownership of the Convertible Promissory Note in the amount of $184,833 (the "Note") and the shares of common stock underlying such Note (the "Shares"), through Apimeds Korea. In fact, as reported in this amendment, the reporting person directly owned the Note and the Shares.